Tools
Lipid-Lowering Drug Therapy
Indications
Atherosclerosis is one of the major causes of coronary heart disease. According to the 2016 Centers for Disease Control and Prevention data, heart disease is the leading cause of death in the United States. Dietary modifications, weight reduction, and exercise are the first line of defense. Patients at an increased risk of cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina—benefit from lipid-lowering medications. These drugs are beneficial when used in conjunction with lifestyle changes and can be used for primary or secondary prevention of cardiovascular events. Primary prevention includes patients without prior events but with risk factors such as diabetes mellitus and hypertension. Secondary prevention includes patients with a history of cardiovascular events. The 2018 American College of Cardiology/American Heart Association guideline emphasizes reducing the risk of atherosclerotic cardiovascular disease (ASCVD) through lipid management.[1] Lipoprotein-modifying agents encompass several classes of drugs, including 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), cholesterol-absorbing inhibitors, fibric acid derivatives, bile acid sequestrants, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and nicotinic acid. There have been numerous advances in pharmacotherapy for lipid management, which have been described along with traditional therapies. A concise summary is provided in the tables below (See Tables. Comparison of Lipid-Lowering Therapies and Advances in Lipid-Lowering Drug Therapy).
Table 1. Comparison of Lipid-Lowering Therapies
| Drug Class | Key Representative Drugs | Primary Mechanism of Action | Primary Lipid Effects | Key Indications | Notable Considerations |
| HMG-CoA reductase inhibitors (statins) | Atorvastatin, rosuvastatin, and simvastatin | Inhibits HMG-CoA reductase (cholesterol synthesis) | ↓ LDL-C, ↓ TG (at higher doses), ↓ Lp(a), and pleiotropic effects | First-line therapy for primary/secondary prevention of ASCVD | Oral, the cornerstone of therapy, SAMS, and rhabdomyolysis |
| Cholesterol absorption inhibitors | Ezetimibe | Inhibits cholesterol absorption (NPC1L1) | ↓ LDL-C, ↓ Apo B, and ↓ non-HDL | Primary hyperlipidemia, mixed hyperlipidemia, and familial hypercholesterolemia; often add-on to statins | Oral and complementary mechanism to statins |
| Fibric acid derivatives (fibrates) | Fenofibrate and gemfibrozil | Activates PPAR-α (enhances TG catabolism) | ↓ TG and ↑ HDL-C (5-20%) | Severe hypertriglyceridemia (to prevent pancreatitis) | Oral, risk of gallstones, and myopathy (with statin) |
| Nicotinic acid (niacin) | Niacin | Inhibits hepatic VLDL synthesis and reduces HDL catabolism | ↑ HDL-C, ↑ LDL-C (modest), and ↓ TG | Limited role in high-risk population | Oral and significant flushing |
| Bile acid sequestrants | Cholestyramine, colestipol, and colesevelam | Bind bile acids in the intestine → prevent reabsorption via enterohepatic circulation → ↑ hepatic conversion of cholesterol to bile acids → ↓ LDL | ↓ LDL-C (modest) and ↑ HDL-C (modest) | Primary hypercholesterolemia; often add-on to statins/niacin and safe in pregnancy | Oral, non-systemic, and gastrointestinal adverse effects |
| Omega-3 fatty acid formulations | Icosapent ethyl | Reduced hepatic VLDL and triglyceride synthesis | ↓ VLDL and ↓ TG | Severe hypertriglyceridemia | Oral and risk of bleeding |
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; Apo B, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; HMG-CoA, 3-Hydroxy-3-methylglutaryl-coenzyme A; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); NPC1L1, Niemann-Pick C1-like 1; PPAR-α, peroxisome proliferator-activated receptor-alpha; SAMS, statin-associated muscle symptoms; TG, triglycerides; VLDL, very-low-density lipoprotein.
Table 2. Advances in Lipid-Lowering Drug Therapy
| Drug Class | Key Representative Drugs | Primary Mechanism of Action | Primary Lipid Effects | Key Indications | Notable Considerations |
| PCSK9 inhibitors (monoclonal antibodies) | Alirocumab and evolocumab | Binds to and inhibits the PCSK9 protein | ↓ LDL-C (significant) and ↓ Lp(a) | HeFH, clinical ASCVD (adjunct to diet/statins); HoFH (Evolocumab) | Injectable (subcutaneous) and significant LDL-C lowering |
| PCSK9 inhibitors (siRNA) | Inclisiran | siRNA targeting PCSK9 mRNA (prevents PCSK9 production) | ↓ LDL-C (significant) and ↓ Lp(a) | Primary hyperlipidemia and HeFH (adjunct to diet/statins) | Injectable (subcutaneous) and favorable dosing (eg, twice yearly) |
| Adenosine triphosphate-citrate lyase inhibitor | Bempedoic acid | Inhibits ACL (upstream cholesterol synthesis) | ↓ LDL-C | Established CVD or high risk, unable to take statins; primary hyperlipidemia, HeFH | Oral, an option for statin-intolerant patients, and risk of tendonitis |
| Microsomal triglyceride transfer protein inhibitor | Lomitapide mesylate | Inhibits MTP (reduces VLDL/chylomicron assembly) | ↓ LDL-C, ↓ total cholesterol and ↓ Apo B | Homozygous familial hypercholesterolemia | FDA box warning— Hepatotoxicity |
| Angiopoietin-like protein inhibitor | Evinacumab | Inhibits ANGPTL3 (enhances lipoprotein lipase activity) | ↓ LDL-C and ↓ TG | Homozygous familial hypercholesterolemia | Injectable (intravenous), highly specialized orphan drug, and multi-targeted approach for severe dyslipidemia |
| ApoC-III inhibitors | Olezarsen | Antisense oligonucleotide (reduction of apoC-III protein leads to increased clearance of plasma TG and VLDL) | ↓ TG and ↓ VLDL | Familial chylomicronemia syndrome | Injection site reactions and thrombocytopenia |
| Cholesteryl ester transfer protein inhibitors | Obicetrapib (investigational) | Inhibits CETP (modulates cholesterol ester transfer) | ↑ HDL-C and ↓ LDL-C | Investigational (no FDA approval for class) | Oral, history of development challenges, and innovation in drug design |
Abbreviations: ACL, adenosine triphosphate-citrate lyase; ANGPTL, angiopoietin-like protein; Apo B, apolipoprotein B; ApoC-III, apolipoprotein C-III; ASCVD, atherosclerotic cardiovascular disease; CETP, cholesteryl ester transfer protein; CVD, cardiovascular disease; FDA, food and drug administration; HeFH, heterozygous familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); mRNA, messenger RNA; MTP, microsomal triglyceride transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; siRNA, small interfering RNA; TG, triglycerides; VLDL, very-low-density lipoprotein.
Food and Drug Administration–Approved Indications with Drug Classes
Statins: Statins are the first-line lipid-lowering drugs. Other therapies, discussed subsequently, are added to increase the efficacy of statins or in cases of statin intolerance or severe hypertriglyceridemia. Statins can lower low-density lipoprotein (LDL) and triglyceride concentrations (at higher doses) while increasing high-density lipoprotein (HDL) concentrations.
Ezetimibe: Ezetimibe impairs cholesterol absorption and lowers low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-HDL in patients with primary hyperlipidemia, mixed hyperlipidemia, and familial hypercholesterolemia.[2]
Fibrates: Fibrates are known to decrease triglycerides by as much as 50% and also increase HDL by 5% to 20%.[3] Despite their effects on lipids, fibrates have less favorable impacts on clinical outcomes.[4] These drugs are primarily used to lower triglycerides and avert the risk of pancreatitis, with an overall modest primary ASCVD prevention benefit.
Nicotinic acid: Nicotinic acid (niacin) significantly raises high-density lipoprotein cholesterol (HDL-C), but its effect on improving patient outcomes in patients on statins has not been demonstrated.[5][6] Niacin use can help lower LDL in combination with statins plus ezetimibe in patients at extremely high cardiovascular risk, such as homozygous or heterozygous familial hypercholesterolemia, but not in secondary prevention.
Bile acid sequestrants: Bile acid sequestrants include cholestyramine, colestipol, and colesevelam. Bile acid sequestrants are indicated for the treatment of primary hypercholesterolemia and are typically used in combination with statins or niacin. Cholestyramine has been shown to decrease cardiovascular mortality and morbidity by 19% compared to placebo and may also benefit patients with type 2 diabetes by decreasing blood sugar levels.[7] Bile acid sequestrants can also rapidly reduce plasma thyroid hormone levels, making them useful for treating refractory thyrotoxicosis.[8] These agents can also raise HDL-C levels.[9][10][11] Bile acid sequestrants can be used to manage pruritus in patients with cholestatic disease and incomplete biliary obstruction.
PCSK9 inhibitors: PCSK9 inhibitors are a new class of drugs approved to lower LDL levels and have been shown to reduce LDL by as much as 60% in patients taking statins. Alirocumab and evolocumab are approved by the Food and Drug Administration (FDA) for adult patients with heterozygous familial hypercholesterolemia or clinical ASCVD who require further lowering of LDL-C in addition to diet modification and maximally tolerated statin therapy.[12][13][14] Evolocumab is also approved by the FDA for adult patients with homozygous familial hypercholesterolemia who require additional lowering of LDL-C, in combination with other LDL-lowering therapies, such as statins or ezetimibe.
Small interfering RNA therapy targeting PCSK9: Inclisiran is a small interfering RNA (siRNA) directed towards PCSK9 messenger RNA.[15][16] Inclisiran is approved by the FDA as an adjunct to diet and statins for primary hyperlipidemia and heterozygous familial hypercholesterolemia. Inclisiran significantly reduced LDL-C levels.[17]
Adenosine triphosphate-citrate lyase inhibitor: Bempedoic acid is approved by the FDA to reduce the risk of myocardial infarction and coronary revascularization in adults with established cardiovascular disease or those at high risk for cardiovascular events who are unable to take recommended statin therapy. Bempedoic acid is also indicated for lowering LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, as an adjunct to dietary modification—either as monotherapy or in combination with other LDL-C-lowering agents.[18][19] Bempedoic acid is typically combined with ezetimibe.[20]
Cholesteryl ester transfer protein inhibitor: Currently, no cholesteryl ester transfer protein (CETP) inhibitors have received FDA approval. These inhibitors are a class of drugs targeting CETP, which facilitates the transfer of cholesteryl esters from HDL to apoB-containing lipoproteins, such as LDL and very-low-density lipoprotein (VLDL), in exchange for triglycerides. CETP inhibitors, including orcetrapib, dalcetrapib, evacetrapib, and anacetrapib, are not approved by the FDA. However, obicetrapib, with better selectivity and lipid-lowering effects, has revived interest in CETP inhibitors.[21] Additional research is required due to potential safety concerns, such as aldosterone-mediated hypertension and electrolyte imbalances.[22][23][24]
Microsomal triglyceride transfer protein inhibitor: Lomitapide mesylate is approved by the FDA as an adjunct to dietary modification and other lipid-lowering treatments to decrease LDL-C, total cholesterol, and Apo B in homozygous familial hypercholesterolemia.[25][26] However, the safety and effectiveness of lomitapide have not been established in patients without homozygous familial hypercholesterolemia, including those with heterozygous familial hypercholesterolemia.
Angiopoietin-like protein inhibitors: Evinacumab is approved by the FDA as an add-on to other LDL-C–lowering treatments for adults and pediatric patients aged 5 or older with homozygous familial hypercholesterolemia.[27][28][29]
Omega-3 fatty acid formulations: Icosapent ethyl is approved by the FDA as an adjunct to control triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL). The trial has shown benefit in cardiovascular mortality.[30][31]
ApoC-III inhibitors: Olezarsen is approved by the FDA for familial chylomicronemia syndrome.[32][33]
Investigational Treatments (Not Approved by the Food and Drug Administration)
Cholesteryl ester transfer protein inhibitor: Currently, no CETP inhibitors have received FDA approval due to safety concerns reported in the clinical trials. These inhibitors are a class of drugs targeting CETP, which facilitates the transfer of cholesteryl esters from HDL to apoB-containing lipoproteins, such as LDL and VLDL, in exchange for triglycerides. CETP inhibitors, including orcetrapib, dalcetrapib, evacetrapib, and anacetrapib, are not approved by the FDA. However, obicetrapib, with better selectivity and lipid-lowering effects, has revived interest in CETP inhibitors.[21] Additional research is required due to potential safety concerns, such as aldosterone-mediated hypertension and electrolyte imbalances.[22][23][24]
ApoC-III inhibitors: Volanesorsen is not approved by the FDA but has received an EMA approval for familial chylomicronemia syndrome.[34]
Lipoprotein(a)-targeting treatments: Several investigational drugs are in advanced development to reduce lipoprotein(a), an independent risk factor for ASCVD. Pelacarsen is an antisense oligonucleotide that binds apolipoprotein(a) messenger RNA, inhibiting its translation and reducing hepatic Lp(a) synthesis.[35] Olpasiran is a siRNA that degrades apolipoprotein(a) messenger RNA via RNA-induced silencing complex-mediated cleavage.[36] Despite differing mechanisms, these agents share the goal of selectively lowering Lp(a).
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Statins
Statins are competitive inhibitors of HMG-CoA reductase, a key enzyme in the biosynthesis of cholesterol.[37] This inhibition increases LDL clearance by upregulating LDL receptors in the liver.[38] Statins also reduce VLDL by affecting hepatic Apo B secretion, modestly raise HDL levels, and lower triglycerides, depending on the statin and dose.[39] LDL cholesterol reductions can reach up to 63%.[40][41] Rosuvastatin and atorvastatin are high-intensity statins, with rosuvastatin being slightly more potent than atorvastatin.[42] Statins are particularly effective in lowering triglycerides when levels exceed 250 mg/dL.[43]
Ezetimibe
Ezetimibe inhibits Niemann-Pick C1-like 1 protein in the intestine and liver, reducing dietary and biliary cholesterol absorption without affecting bile acid excretion or cholesterol synthesis.[44][45] As a result, it decreases cholesterol stores in the liver, increases the clearance of cholesterol from the bloodstream, and upregulates the expression of LDL receptors.
Fibrates
Fibrates activate peroxisome proliferator-activated receptor-alpha, leading to downregulation of apolipoprotein C-III and upregulation of apolipoprotein A-I, lipoprotein lipase, and fatty acid transport protein. This activation promotes VLDL catabolism and the clearance of triglyceride-rich particles, resulting in a 30% to 60% reduction in plasma triglycerides and a modest increase in HDL levels.
Nicotinic Acid (Niacin)
The exact mechanism is not fully understood, but it may involve partial inhibition of free fatty acid release from adipose tissue and increased lipoprotein lipase activity, promoting triglyceride removal from plasma.
Bile Acid Sequestrants
Bile acid sequestrants bind to bile acids in the intestine, preventing their reabsorption and reducing hepatic cholesterol levels. The decrease in intrahepatic cholesterol upregulates LDL receptors, lowering blood cholesterol and minimally increasing HDL-C.[46][47][46] Triglycerides may rise; these agents are contraindicated if triglycerides exceed 400 mg/dL.
Icosapent Ethyl
Icosapent ethyl reduces hepatic VLDL and triglyceride synthesis and increases triglyceride clearance from circulating VLDL particles.
PCSK9 Inhibitors
PCSK9 inhibitors bind to LDL receptors on hepatocytes, promoting their degradation and increasing plasma LDL-C levels. PCSK9 antibodies block this interaction, thereby increasing LDL receptor expression and lowering LDL-C levels.[48]
Bempedoic Acid
Bempedoic acid inhibits ATP-citrate lyase, upstream of HMG-CoA reductase, reducing LDL-C levels.[19] This agent also suppresses vascular smooth muscle proliferation via AMP-activated protein kinase-acetyl-CoA carboxylase signaling. Unlike statins, it is a prodrug that is activated in the liver but not in skeletal muscle, potentially reducing muscle-related adverse effects.
Inclisiran
Inclisiran is a siRNA that targets PCSK9 messenger RNA in hepatocytes, lowers PCSK9 synthesis, and reduces LDL-C by about 50% with twice-yearly dosing.[15][16]
CETP Inhibitors (eg, obicetrapib)
CETP inhibitors block CETP, reducing cholesterol transfer from HDL to ApoB lipoproteins. CETP inhibitors modestly decrease LDL-C levels and increase HDL levels. Currently, CETP inhibitors remain investigational, with no FDA-approved agents.
ApoC-III Inhibitors (eg, olezarsen)
These antisense oligonucleotides reduce ApoC-III production, enhancing triglyceride clearance. ApoC-III Inhibitors are approved for familial chylomicronemia syndrome.[32]
Lomitapide
Lomitapide is an oral microsomal triglyceride transfer protein inhibitor that prevents assembly and secretion of ApoB-containing lipoproteins (VLDL and chylomicrons), lowering LDL-C, total cholesterol, and ApoB. This inhibitor is approved by the FDA for homozygous familial hypercholesterolemia.[49]
Evinacumab
Evinacumab is a monoclonal antibody that inhibits angiopoietin-like protein 3, enhancing lipoprotein lipase activity and lowering LDL-C and triglycerides. This antibody is approved by the FDA for homozygous familial hypercholesterolemia.[50][51]
Administration
Available Dosage Forms and Strengths
Statins, such as atorvastatin, rosuvastatin, and simvastatin, are formulated as oral immediate-release tablets. In contrast, lovastatin is available in both immediate-release and extended-release forms. Ezetimibe is offered as a single oral tablet formulation. Fenofibrate is available in multiple oral forms, including immediate-release tablets, extended-release tablets, and both standard and micronized capsules. Gemfibrozil is limited to oral tablets. Niacin is available in both immediate- and extended-release oral tablets. Extended release is aimed at reducing flushing. Bile acid sequestrants differ by agent. Cholestyramine is available as a powder for oral suspension, colestipol is available as granules and tablets, and colesevelam is available as tablets and a powder for oral suspension. In the newer class of lipid-lowering agents, PCSK9 inhibitors, such as alirocumab and evolocumab, are administered subcutaneously using prefilled devices. Inclisiran is administered as a subcutaneous injection, typically in a clinical setting. Bempedoic acid is available as an oral tablet. Lomitapide is an oral capsule. Evinacumab is given through intravenous infusion. Olezarsen is a subcutaneous injectable formulation.
Dosage
Statins: Most endogenous cholesterol synthesis predominantly occurs at night, during the fasting state. Consequently, it has historically been recommended to administer statins, particularly those with shorter half-lives, in the evening or at bedtime to align with this peak synthesis.[52] However, for longer-acting statins such as rosuvastatin or atorvastatin, the timing of administration is less critical, and they can be taken effectively at any time of day. Nevertheless, taking them at approximately the same time each day is generally recommended to promote patient adherence and consistent drug levels. Some studies have suggested a regimen of statins every other day to reduce costs and improve the tolerability of statins. In contrast, major outcome trials of statins base their results on daily statin therapy. Therefore, taking statins every other day is not a common practice, except in patients who are unable to tolerate statins.[53][54][55] Statin therapy is selected based on ASCVD risk estimation rather than fixed dosing. High-intensity statins, such as atorvastatin and rosuvastatin, are typically initiated at doses of 40 to 80 mg and 20 to 40 mg, respectively. Moderate-intensity options, including simvastatin (20-40 mg daily) and pravastatin (40-80 mg daily), may be considered for individuals at lower risk or older adults. Dose titration is individualized based on LDL-C response, tolerability, and the target risk profile, with lipid panels monitored at 4 weeks to 12 weeks and then periodically thereafter.
Ezetimibe: Ezetimibe can be taken with meals and is safe for administration with a statin or a fibrate. This drug may be taken at the same time as fenofibrate or HMG-CoA reductase inhibitors; however, it is recommended to take it at least 1 hour before or 4 hours after taking bile acid sequestrants.
Fibrates: Fibrates are typically dosed 30 minutes before meals. Fibrates, such as fenofibrate, are initiated at 48 to 145 mg once daily with food (depending on the formulation), whereas gemfibrozil is administered at 600 mg twice daily. Dose adjustment is necessary in renal impairment, and combination with statins increases myopathy risk, warranting careful selection and monitoring.
Nicotinic acid: Nicotinic acid is administered orally with a meal and is typically initiated at 100 mg 3 times a day, with the dose gradually increased as needed.[5] LDL-C lowering occurs at doses greater than 1.5 g/d.
Bile acid sequestrants: Bile acid sequestrants are available as granules or tablets. Cholestyramine should ideally be taken with breakfast when given to treat pruritus associated with cholestasis. Symptoms of pruritus are less frequent in the morning, as the belief is that the pruritogenic factors concentrate in the gallbladder during overnight fasting. Cholestyramine is started at 4 g once or twice daily and titrated at monthly intervals to a typical range of 8 to 16 g daily in divided doses. Colesevelam is typically initiated at a dose of 3.75 g daily. Gastrointestinal tolerability often limits dose escalation.
PCSK9 inhibitors: PCSK9 inhibitors are administered by subcutaneous injections, with enzyme inactivation occurring within 4 to 8 hours. Evolocumab is administered at 140 mg subcutaneously every 2 weeks or 420 mg monthly. Alirocumab may be initiated at 75 mg every 2 weeks and subsequently increased to 150 mg based on the LDL-C response. Cost is the primary limiting factor for PCSK9 inhibitors.
Bempedoic acid: Bempedoic acid is administered orally at a dose of 180 mg once daily, with or without food.[56] Bempedoic acid and ezetimibe contain 180 mg of bempedoic acid and 10 mg of ezetimibe, taken once daily.
Inclisiran: Inclisiran is supplied as a single-dose prefilled syringe for subcutaneous use. The initial dose is 284 mg as a single injection, which is repeated at 3 months and then every 6 months thereafter.
Lomitapide: Lomitapide is available in oral capsules in strengths of 5, 10, 20, and 30 mg. The clinicians should start with 5 mg and increase the dose gradually. The lomitapide dose should not exceed 30 mg/d.
Evinacumab: Evinacumab is administered as an intravenous infusion, with a typical dose of 15 mg/kg every 4 weeks.
Olezarsen: Olezarsen is administered subcutaneously at a dose of 80 mg once a month.[32]
Icosapent ethyl: The recommended daily dosage of icosapent ethyl is 4 g, administered with food either as 4 0.5-g capsules twice daily or as 2 1-g capsules twice daily.
Specific Patient Populations
Hepatic impairment: Statins are contraindicated in active liver disease (alanine aminotransferase/aspartate aminotransferase (ALT/AST) >3 times the upper limit of normal); mild transaminase elevation allows cautious use with liver function test monitoring. Fibrates are contraindicated in severe hepatic impairment; monitor liver function tests in mild cases. Bile acid sequestrants are considered safe (nonsystemic), but monitoring for vitamin malabsorption is recommended in cases of cholestasis. Lomitapide is contraindicated in moderate-to-severe impairment. Evinacumab and icosapent ethyl are considered safe; however, olezarsen requires regular monitoring of liver function tests.
Renal impairment: Fibrates are contraindicated in patients with severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m²); fenofibrate requires dose adjustment. Rosuvastatin requires dose reduction in patients with chronic kidney disease, whereas atorvastatin requires minimal adjustment. Ezetimibe is considered safe but should be monitored when used concurrently with statins. Bile acid sequestrants are generally safe; however, there is a risk of hyperchloremic acidosis in patients with advanced chronic kidney disease. Lomitapide and evinacumab have limited data in renal impairment and should be used with caution. Icosapent ethyl and olezarsen are generally safe, though monitoring for bleeding risk and platelet levels is advised.
Pregnancy considerations: Statins, ezetimibe, lomitapide, and bempedoic acid are contraindicated during pregnancy due to potential teratogenic effects; recent data suggest a reevaluation of the risks associated with statins.[57] Fibrates are generally avoided, except in cases of severe hypertriglyceridemia (triglycerides >1000 mg/dL), under the guidance of a specialist. Bile acid sequestrants are preferred (nonsystemic), but the mother should also supplement with fat-soluble vitamins.[58]
Breastfeeding considerations: Statins and ezetimibe are not recommended during lactation, as potential excretion in breast milk may interfere with neonatal lipid metabolism.[59][60] Fibrates are avoided due to limited safety data. Bile acid sequestrants are considered safe (nonsystemic); however, maternal and infant nutrition should be closely monitored due to the potential for malabsorption.[61][62]
Pediatric patients: Pravastatin is approved for patients aged 8 or older, simvastatin for those aged 10 or older, and rosuvastatin for those aged 8 or older, specifically in cases of heterozygous familial hypercholesterolemia or homozygous familial hypercholesterolemia. Ezetimibe has been approved for patients older than 10. Bile acid sequestants are used for homozygous familial hypercholesterolemia but are poorly tolerated. Evolocumab has been approved for patients aged 10 or older with familial hypercholesterolemia. Evinacumab is approved for use in patients aged 5 or older with homozygous familial hypercholesterolemia.[63] Lomitapide is approved for use in patients aged 18 or older with homozygous familial hypercholesterolemia.[64]
Older patients: Statins remain the first-line therapy for ASCVD; initiating treatment at lower doses is recommended to minimize the risk of myopathy. Ezetimibe and bile acid sequestrants are tolerated, but gastrointestinal side effects may limit use. Fibrates may increase the risk of renal adverse effects; therefore, it is essential to closely monitor renal function. PCSK9 inhibitors and bempedoic acid are well-tolerated alternatives for statin-intolerant older patients.
Adverse Effects
Statins
Statins are among the safest medications for lowering lipids, with muscle injury being the most common adverse effect.[65][66] Other adverse effects include new-onset diabetes mellitus and hepatotoxicity. Lipophilic statins (eg, simvastatin, lovastatin, atorvastatin, and fluvastatin) may cause more adverse events than hydrophilic statins (eg, pravastatin and rosuvastatin).[67] Muscle injury can range from mild myalgias to, rarely, myonecrosis or rhabdomyolysis.[66][68] A meta-analysis of 42 randomized trials found little to no excess risk of myalgias, creatine kinase elevations, rhabdomyolysis, or therapy discontinuation compared to placebo. However, muscle complaints are relatively common in clinical practice.[69][70] High-dose atorvastatin (80 mg daily) has shown a higher incidence of myalgia compared to placebo, whereas clinically significant myonecrosis (creatine kinase >10 times normal) occurs in <0.5% of patients in large trials.[71][72][73][71] Risk increases with higher doses and lipophilic statins; simvastatin and lovastatin carry the highest risk, fluvastatin and pravastatin the lowest.[74] Patients with preexisting neuromuscular diseases (eg, myasthenia gravis, mitochondrial myopathy, McArdle disease, acid maltase deficiency, and amyotrophic lateral sclerosis) are more susceptible.[75][76] Vigorous exercise may increase risk. Creatine kinase measurement can help diagnose severe myositis or myonecrosis; however, many patients do not exhibit creatine kinase elevations, making routine monitoring generally unnecessary. A baseline creatine kinase level is recommended before initiation of treatment.[77][78][79] Management includes assessing drug interactions, vitamin D deficiency, and hypothyroidism, switching statins, or trialing alternate-day dosing.[80] Coenzyme Q10 may be beneficial, but the evidence is limited, and further large-scale studies are needed.[81]
Ezetimibe
Ezetimibe can cause fatigue, diarrhea, headache, rhinorrhea, body aches, back pain, chest pain, joint pain, sore throat, and elevated serum transaminases.
Fibrates
Fibrates commonly cause dyspepsia and may also produce fatigue, vertigo, pancytopenia, and elevated serum transaminases.
Nicotinic Acid (Niacin)
Niacin is often poorly tolerated, with flushing occurring in 80% of patients and pruritus, paresthesia, or nausea in the remaining 20%.[82] Symptoms last 10 to 20 minutes and can be reduced by taking aspirin or ibuprofen 60 minutes prior to onset. Other adverse effects include hyperglycemia, hyperuricemia, liver dysfunction, hypotension with vasodilators, increased infection risk, bleeding due to decreased platelet function, and elevated homocysteine levels.[83][84][85]
Bile Acid Sequestrants
Bile acid sequestrants commonly cause gastrointestinal adverse effects, including nausea, bloating, cramping, and elevated liver enzymes. Dyspepsia and bloating can be reduced by fully suspending cholestyramine in liquid several hours before ingestion.
PCSK9 Inhibitors
PCSK9 inhibitors may cause local injection site reactions, such as erythema, pain, and bruising. Muscle toxicity and elevations in creatine kinase have not been reported.[86][87][88]
Inclisiran
Inclisiran is generally well tolerated; mild-to-moderate injection site reactions (erythema, pain, swelling) are possible. Other adverse events include arthralgia and bronchitis.
Bempedoic Acid
Bempedoic acid may lead to hyperuricemia, precipitating gout flares, especially in predisposed individuals, and may increase the risk of tendonitis or tendon rupture.[89] Co-administration with fluoroquinolones should be avoided.
Lomitapide
Lomitapide has a distinct adverse profile with a black box warning for hepatotoxicity. Patients may develop elevated transaminases, hepatic steatosis, diarrhea, nausea, vomiting, and abdominal discomfort. Lomitapide may also cause fat-soluble vitamin deficiencies, requiring supplementation and monitoring.
Evinacumab
Evinacumab can cause infusion-related reactions, including flushing, chills, or dyspnea. Other reported adverse effects include nasopharyngitis, headache, and flu-like symptoms.[90]
Olezarsen
Olezarsen may cause thrombocytopenia and arthralgia.[91]
Icosapent Ethyl
Icosapent ethyl is associated with an increased risk of atrial fibrillation or atrial flutter and increased bleeding risk.[30]
Drug-Drug Interactions
Statins: Simvastatin and lovastatin are contraindicated with potent CYP3A4 inhibitors such as clarithromycin, itraconazole, and protease inhibitors due to the risk of severe myopathy or rhabdomyolysis. Atorvastatin interacts with CYP3A4 inhibitors and inducers, requiring dose adjustment or substitution with non-CYP3A4 substrates. Rosuvastatin has fewer CYP-mediated interactions; however, it should be used cautiously in combination with cyclosporine and gemfibrozil, as these medications can increase its plasma concentration. Fibrates combined with statins increase the risk of myopathy, particularly in older adults or those with renal impairment. Concomitant use of statins with warfarin may enhance anticoagulant effects and necessitate international normalized ratio (INR) monitoring. Grapefruit juice should be avoided with simvastatin and atorvastatin due to inhibition of intestinal CYP3A4.
Ezetimibe: When co-administered with cyclosporine, ezetimibe increases its own exposure and may alter cyclosporine levels; therefore, close monitoring is recommended. When used in conjunction with warfarin, INR levels should be monitored, although evidence of a consistent interaction is limited. Co-administration with fibrates, especially gemfibrozil, may increase the risk of gallstones and liver enzyme elevations.
Fibrates: Gemfibrozil significantly increases statin levels by inhibiting glucuronidation, particularly with simvastatin and lovastatin, thereby increasing the risk of rhabdomyolysis. Concomitant use of fibrates and anticoagulants, such as warfarin, can potentiate the anticoagulant effects; therefore, careful INR monitoring is recommended. Co-administration with bile acid sequestrants may reduce fibrate absorption, so fibrates should be taken at least 1 hour before or 4 to 6 hours after the resin.
Nicotinic acid: Combining nicotinic acid with statins increases the risk of hepatotoxicity and myopathy; therefore, monitoring of liver function and muscle symptoms is recommended. Alcohol may exacerbate flushing and hepatotoxic effects of niacin. Antihypertensive agents may exhibit an enhanced hypotensive effect when combined with niacin, likely due to its vasodilatory properties. Fibrates have limited interactions with CYP enzymes; however, caution is advised when used concomitantly with other hepatotoxic drugs.
Bile acid sequestrants: Bile acid sequestrants can impair the absorption of various medications, including warfarin, digoxin, levothyroxine, and oral contraceptives. Therefore, these medications should be administered at least 1 hour before or 4 to 6 hours after bile acid sequestrants. Bile acid sequestrants may reduce the absorption of fat-soluble vitamins (A, D, E, and K), potentially affecting coagulation or bone health with long-term use. No significant CYP-mediated interactions are known.
PCSK9 inhibitors: PCSK9 inhibitors are monoclonal antibodies that are not metabolized by CYP450 enzymes, minimizing systemic drug interactions. No clinically significant pharmacokinetic interactions have been identified; however, ongoing surveillance is advised.
Inclisiran: Inclisiran has minimal potential for drug-drug interactions. Current evidence does not indicate significant interactions; however, post-marketing surveillance is necessary to identify drug interactions. Concurrent use with other lipid-lowering agents is generally well tolerated.
Bempedoic acid: Bempedoic acid increases serum concentrations of simvastatin and pravastatin via inhibition of OATP1B1/1B3 transporters; lower statin doses are recommended when co-administered. Uric acid levels may increase with bempedoic acid; caution is advised in patients on diuretics or with a history of gout. Co-administration with fluoroquinolones should be avoided due to the risk of tendonitis or tendon rupture.
Lomitapide: Lomitapide is a potent inhibitor and substrate of CYP3A4; its use with potent CYP3A4 inhibitors is contraindicated due to the risk of hepatotoxicity. This drug also inhibits P-glycoprotein and may increase plasma levels of digoxin and other substrates. Warfarin levels may increase; close INR monitoring is required when initiating or discontinuing lomitapide. Alcohol should be avoided due to the potential for hepatotoxicity.[92]
Evinacumab: Evinacumab is not metabolized by CYP enzymes and has minimal known interaction potential. No clinically significant drug-drug interactions have been reported.[93] As with other biologics, ongoing monitoring is crucial in polypharmacy settings or when using immunomodulatory agents.
Icosapent ethyl: Icosapent ethyl may increase the risk of bleeding when used in combination with anticoagulants or antiplatelet agents; therefore, bleeding parameters should be closely monitored. Icosapent ethyl may alter platelet aggregation; thus, caution is advised in patients receiving dual antiplatelet therapy.[30]
Olezarsen: Olezarsen currently shows minimal risk of drug-drug interactions based on clinical data and is not metabolized by CYP enzymes. Additional clinical data are required to establish its long-term safety profile.[94]
Contraindications
A hypersensitivity reaction, such as anaphylaxis or angioedema, is an absolute contraindication for all lipid-lowering agents.
Statins
Statins are contraindicated in patients with active hepatic disease or unexplained, persistent elevations in aminotransferase levels. These agents should not be used during pregnancy or breastfeeding, as cholesterol is essential for fetal and infant steroid synthesis and the development of cell membranes. However, recent studies have begun to reexamine this risk.[95] Statins are also associated with an increased risk of developing diabetes mellitus; caution is advised in patients with elevated blood glucose or HbA1c levels. Drug interactions that inhibit cytochrome P450 3A4 (CYP3A4) can increase the risk of statin-induced myopathy. Such agents include cyclosporine, macrolide antibiotics, systemic azole antifungals, HIV or hepatitis C virus protease inhibitors, gemfibrozil, diltiazem, verapamil, amiodarone, colchicine, and grapefruit juice.[96][97]
Ezetimibe
Ezetimibe is contraindicated when used with an HMG-CoA reductase inhibitor in patients with active liver disease or unexplained elevated transaminase levels. When used alone, ezetimibe is not contraindicated in mild-to-moderate hepatic impairment. Ezetimibe should be avoided during pregnancy and breastfeeding when used in combination with a statin.
Fibrates
Fibrates are contraindicated in patients with active liver disease, including primary biliary cirrhosis, or unexplained, persistent liver function abnormalities; severe renal impairment or end-stage renal disease, including those on dialysis; preexisting gallbladder disease; and during breastfeeding.
Nicotinic Acid
Nicotinic acid is contraindicated in active hepatic disease or persistent elevations in hepatic transaminases, with an increased risk when used in combination with statins, fibrates, or similar agents. Additional contraindications include active peptic ulcer disease and arterial bleeding.
Bile Acid Sequestrants
Bile acid sequestrants are contraindicated in severe hypertriglyceridemia and complete biliary obstruction. Because they are not systemically absorbed, these agents are generally safe for patients unable to tolerate other lipid-lowering drugs due to liver dysfunction.
PCSK9 Inhibitors
PCSK9 inhibitors do not typically cause muscle toxicity or elevated hepatic enzymes and have no specific contraindications beyond hypersensitivity.
Inclisiran and Bempedoic Acid
Inclisiran and bempedoic acid are contraindicated in patients with known hypersensitivity reactions to the drug or its components.
Lomitapide
Lomitapide is contraindicated during pregnancy and with concomitant use of strong or moderate CYP3A4 inhibitors. This agent should not be used in patients with moderate or severe hepatic impairment, active liver disease, or unexplained abnormal liver function tests.[98]
Evinacumab
Evinacumab is contraindicated in patients with a history of prior hypersensitivity reactions, as infusion-related reactions may occur.[99]
Olezarsen
Olezarsen is contraindicated in patients with known hypersensitivity reactions.
Icosapent Ethyl
Icosapent ethyl is contraindicated in individuals with known hypersensitivity or fish allergy.
Boxed Warning
Lomitapide: Lomitapide carries a risk of hepatotoxicity, including elevated ALT and AST levels, and can cause hepatic steatosis that may progress to cirrhosis. The dose should be adjusted if ALT or AST levels reach ≥3 times the upper limit of normal and discontinued if clinically significant liver injury develops. Due to these risks, lomitapide is available only through the Risk Evaluation and Mitigation Strategy program and should be used exclusively in patients with confirmed homozygous familial hypercholesterolemia.[98]
Monitoring
Clinicians should assess the patient's lipid profile 4 to 8 weeks after initiating therapy and then periodically every 6 to 12 months to evaluate treatment efficacy.
Statins
Moderate-intensity statin therapy typically lowers LDL cholesterol by 30% to 50% from baseline, whereas high-intensity therapy can reduce LDL cholesterol by more than 50%. Routine liver enzyme monitoring in asymptomatic patients is not recommended, as severe liver injury is uncommon.[100] The FDA recommends baseline liver function tests before starting therapy, with subsequent testing guided by clinical indications.[101] Decisions regarding statin intolerance should incorporate both patient-reported symptoms and clinician evaluation, emphasizing the importance of shared decision-making.[101]
Ezetimibe
Liver function tests should be monitored, and signs of cholelithiasis should be observed when used in combination with statins or fibrates. Therapy should be discontinued if ALT elevations exceed 3 times the upper limit of normal and persist.[102]
Fibrates
Liver and renal function, as well as complete blood counts, should be monitored due to the risk of pancytopenia. Gallstone formation is a known risk.[103]
Nicotinic acid
Blood glucose, coagulation profile, and liver function should be monitored due to risks of hyperglycemia, bleeding abnormalities, and hepatotoxicity.
Lomitapide
Baseline and ongoing monitoring of ALT, AST, alkaline phosphatase, and total bilirubin is required due to the risk of hepatotoxicity. Dose adjustment is recommended if ALT or AST are ≥3 times the upper limit of normal, and therapy should be discontinued in cases of severe hepatotoxicity.[98]
Inclisiran
Lipid profiles should be monitored to assess efficacy; no additional routine laboratory testing is currently mandated.
Bempedoic Acid
Periodic liver enzyme testing and uric acid measurement are advised. Exercise caution in patients with preexisting gout and monitor for tendonitis.
Evinacumab (Angiopoietin-like Protein 3 Inhibitor)
Lipid panel monitoring is recommended. Routine liver or renal tests are not required unless clinically indicated.
Icosapent Ethyl
Bleeding risk should be monitored, especially in patients receiving anticoagulant or antiplatelet therapy. PT/INR should be assessed as indicated, and a 12-lead electrocardiogram should be considered if atrial fibrillation is suspected.[104]
Olezarsen
Platelet counts, liver function tests, and lipid profiles should be monitored.
Toxicity
Statins
Rhabdomyolysis is a rare but severe and potentially fatal complication of statin therapy. Management is primarily supportive and includes immediate discontinuation of the offending drug. Treatment should also address electrolyte abnormalities, particularly hyperkalemia, which can lead to life-threatening arrhythmias.
Ezetimibe
When used in combination with a statin, ezetimibe may increase the risk of muscle toxicity, particularly in older adults (those older than 65), patients with renal impairment, or those with hypothyroidism. Co-administration with cyclosporine significantly increases ezetimibe exposure, with plasma concentrations rising 2.3- to 12-fold, increasing the risk of toxicity.[105]
Fibrates
Fibrates can cause myopathy and, rarely, rhabdomyolysis—especially when used concurrently with statins. The risk is higher with gemfibrozil compared to fenofibrate.[106]
Bile Acid Sequestrants
Bile acid sequestrants can impair the absorption of fat-soluble vitamins, particularly vitamin K, which can lead to abnormalities in clotting factors. These agents may also reduce the absorption of several medications, including statins, ezetimibe, warfarin, nonsteroidal anti-inflammatory drugs, and propranolol. To minimize interactions, other medications should be taken at least 1 hour before or 4 hours after bile acid sequestrants such as cholestyramine.[107]
Niacin (Nicotinic Acid)
Flushing is a common adverse effect resulting from prostaglandin-mediated vasodilation. Pretreatment with aspirin or laropiprant can reduce the severity of flushing.[108]
Lomitapide
As noted previously, lomitapide carries a significant risk of hepatotoxicity, which may necessitate discontinuation of therapy.[98]
Bempedoic Acid
Bempedoic acid inhibits the renal tubular organic anion transporter 2 (OAT2), leading to increased serum uric acid levels and a potential risk of hyperuricemia or gout. Monitoring of uric acid is recommended, with initiation of urate-lowering therapy if symptoms occur. Bempedoic acid has also been associated with an increased risk of tendon rupture—particularly of the biceps, rotator cuff, or Achilles tendon. Risk factors include age older than 60, concurrent corticosteroid or fluoroquinolone use, and renal impairment. The drug should be discontinued if tendinitis or tendon rupture is suspected.[109]
Icosapent Ethyl
Overdose is uncommon but may increase bleeding risk. Management is supportive.
PCSK9 Inhibitors and Inclisiran
No serious toxicities have been reported to date. However, long-term safety data remain limited. Management of overdose is supportive.
Olezarsen
Olezarsen may cause thrombocytopenia. Long-term safety data are not yet available. In cases of overdose, complete blood counts should be monitored, and supportive care provided as necessary.
General Recommendation
For all lipid-lowering agents, consultation with the Poison Control Center is advised for the most current recommendations regarding overdose management and emerging toxicities.
Enhancing Healthcare Team Outcomes
The effectiveness of lipid-lowering therapy in reducing cardiovascular morbidity and mortality depends heavily on patient-centered care, adherence, and coordinated interprofessional collaboration. Each member of the healthcare team plays a vital role in ensuring optimal outcomes, minimizing adverse effects, and supporting long-term therapy success.
Interprofessional Communication and Care Coordination
Effective communication among primary care clinicians, nurses, pharmacists, and other allied healthcare professionals is central to optimizing lipid management. Primary care clinicians typically initiate lipid-lowering therapy based on ASCVD risk, whereas cardiologists and endocrinologists provide expert input for refractory cases and complex lipid disorders, including homozygous familial hypercholesterolemia. Pharmacists contribute by reviewing medication profiles, identifying drug-drug interactions, and counseling patients on adherence strategies and adverse effect management. Nurses reinforce patient education, promote adherence, monitor clinical response, and report symptoms of myopathy or hepatotoxicity promptly. Coordination among these healthcare professionals ensures continuity of care, patient safety, and consistent communication.
Patient Adherence and Counseling Strategies
Medication adherence is the cornerstone of treatment success. Many patients discontinue statins due to perceived or actual muscle-related adverse effects. Clinicians should address these concerns empathetically and emphasize the long-term cardiovascular benefits of continued therapy. Strategies include switching to a different statin, implementing alternate-day dosing, or considering adjuncts such as coenzyme Q10 to improve tolerability. Reinforcing adherence through clear communication and motivational interviewing can significantly enhance long-term compliance and outcomes.
Evidence-Based Therapeutic Integration
Interprofessional teams must apply evidence-based practices when selecting and monitoring lipid-lowering agents. In patients with severe hypertriglyceridemia (triglycerides >1000 mg/dL), fibrates, niacin, and prescription omega-3 fatty acids may be indicated to reduce triglycerides to below 500 mg/dL and lower the risk of pancreatitis. In acute inpatient settings, intravenous insulin may be used to reduce triglycerides and prevent pancreatitis.[110]
Major clinical trials have demonstrated the benefit of combination and novel therapies:
- FOURIER: PCSK9 inhibition reduced myocardial infarction and stroke, though not overall mortality.[111]
- ODYSSEY OUTCOMES: Alirocumab provided a 2% absolute risk reduction in major adverse cardiovascular events.[86]
- IMPROVE-IT: Adding ezetimibe to simvastatin lowered cardiovascular event rates over 6 years compared to statin monotherapy.[112]
- REDUCE-IT: Icosapent ethyl (4 g/d) produced a 4.8% absolute reduction in cardiovascular events and 0.9% reduction in cardiovascular death at 4.9 years in high-risk patients with residual hypertriglyceridemia on statins.[113]
- Conversely, studies of mixed omega-3 fatty acid supplements (eicosapentaenoic acid + docosahexaenoic acid) have not consistently demonstrated cardiovascular benefit.[114]
Ethical and Patient-Centered Considerations
Ethical care in lipid management requires transparency, shared decision-making, and individualized therapy selection based on patient values, comorbidities, and risk tolerance. Healthcare providers should discuss both benefits and potential adverse effects openly, fostering informed consent and patient trust. Cultural sensitivity and health literacy must be prioritized, ensuring that patients understand the purpose, risks, and expectations of therapy.
Team Performance and Continuous Improvement
Regular interdisciplinary case reviews, use of shared electronic health records, and structured care pathways enhance team performance and reduce therapeutic inertia. Incorporating pharmacists and nurses in follow-up monitoring improves medication reconciliation, safety checks, and timely dose adjustments. Continuing education for all team members on evolving guidelines and trial data supports evidence-based, high-quality lipid management.
Ultimately, lipid-lowering therapy achieves its greatest impact when guided by an engaged, communicative, and ethically grounded interprofessional team. Statins remain the foundation of therapy; however, individualized regimens incorporating nonstatin agents, implemented through coordinated team efforts, yield the best outcomes for patient safety, adherence, and long-term cardiovascular health.
References
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18:139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10 [PubMed PMID: 30586774]
Level 1 (high-level) evidenceSizar O, Nassereddin A, Talati R. Ezetimibe. StatPearls. 2025 Jan:(): [PubMed PMID: 30422474]
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. The New England journal of medicine. 1999 Aug 5:341(6):410-8 [PubMed PMID: 10438259]
Level 1 (high-level) evidenceWang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. The Cochrane database of systematic reviews. 2015 Oct 25:2015(10):CD009580. doi: 10.1002/14651858.CD009580.pub2. Epub 2015 Oct 25 [PubMed PMID: 26497361]
Level 1 (high-level) evidenceProbstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Archives of internal medicine. 1994 Jul 25:154(14):1557-9 [PubMed PMID: 8031204]
Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. Journal of lipid research. 1981 Jan:22(1):24-36 [PubMed PMID: 7217784]
Handelsman Y. Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes care. 2011 May:34 Suppl 2(Suppl 2):S244-50. doi: 10.2337/dc11-s237. Epub [PubMed PMID: 21525463]
Yang Y, Hwang S, Kim M, Lim Y, Kim MH, Lee S, Lim DJ, Kang MI, Cha BY. Refractory Graves' Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy. Endocrinology and metabolism (Seoul, Korea). 2015 Dec:30(4):620-5. doi: 10.3803/EnM.2015.30.4.620. Epub 2015 Sep 22 [PubMed PMID: 26394731]
Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England journal of medicine. 1990 Nov 8:323(19):1289-98 [PubMed PMID: 2215615]
Level 1 (high-level) evidenceKnapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, Davidson MH. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. The American journal of medicine. 2001 Apr 1:110(5):352-60 [PubMed PMID: 11286949]
Level 1 (high-level) evidence. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II. Archives of internal medicine. 1993 Jun 14:153(11):1321-9 [PubMed PMID: 8507122]
Level 1 (high-level) evidenceBao X, Liang Y, Chang H, Cai T, Feng B, Gordon K, Zhu Y, Shi H, He Y, Xie L. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal transduction and targeted therapy. 2024 Jan 8:9(1):13. doi: 10.1038/s41392-023-01690-3. Epub 2024 Jan 8 [PubMed PMID: 38185721]
Xiao G, Gao S, Xie Y, Wang Z, Shu M. Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis. Medicina (Kaunas, Lithuania). 2024 Oct 8:60(10):. doi: 10.3390/medicina60101646. Epub 2024 Oct 8 [PubMed PMID: 39459433]
Level 1 (high-level) evidenceMa H, Ma W, Liu Y, Chen L, Ding P. Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels. Reviews in cardiovascular medicine. 2025 Apr:26(4):26980. doi: 10.31083/RCM26980. Epub 2025 Apr 25 [PubMed PMID: 40351695]
Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovascular research. 2024 Oct 14:120(12):1400-1410. doi: 10.1093/cvr/cvae109. Epub [PubMed PMID: 38753448]
Taub PR, Gutierrez A, Wewers D, Garcia Cantu E, Cao H, Deck C, Lesogor A, Ott D, Mena-Madrazo J, Zang X, Wright RS. Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. Journal of the American College of Cardiology. 2025 Jul 22:86(3):196-208. doi: 10.1016/j.jacc.2025.04.049. Epub 2025 May 5 [PubMed PMID: 40392667]
Level 1 (high-level) evidenceAlaíz ÁR, Gudino LC, de la Isla LP, Pardo HG, Calle DG, Miramontes-González JP. Inclisiran: Efficacy in Real World-Systematic Review and Meta-Analysis. Journal of clinical medicine. 2025 Jun 12:14(12):. doi: 10.3390/jcm14124163. Epub 2025 Jun 12 [PubMed PMID: 40565909]
Level 1 (high-level) evidenceKulshreshtha M. An Update on New Cholesterol Inhibitor: Bempedoic Acid. Current cardiology reviews. 2022:18(2):e141221198875. doi: 10.2174/1573403X17666211214111658. Epub [PubMed PMID: 34906059]
De Filippo O, D'Ascenzo F, Iannaccone M, Bertaina M, Leone A, Borzillo I, Ravetti E, Solano A, Pagliassotto I, Nebiolo M, Bruno F, Giacobbe F, Muscoli S, Monticone S, Brizzi MF, Biondi Zoccai G, De Ferrari GM. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovascular diabetology. 2023 Nov 28:22(1):324. doi: 10.1186/s12933-023-02022-z. Epub 2023 Nov 28 [PubMed PMID: 38017541]
Level 1 (high-level) evidenceBhagavathula AS, Al Matrooshi NO, Clark CCT, Rahmani J. Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials. Clinical drug investigation. 2021 Jan:41(1):19-28. doi: 10.1007/s40261-020-00989-1. Epub 2020 Dec 23 [PubMed PMID: 33368025]
Level 1 (high-level) evidenceNicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Goldberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh A, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. American heart journal. 2024 Aug:274():32-45. doi: 10.1016/j.ahj.2024.05.002. Epub 2024 May 4 [PubMed PMID: 38705341]
Chang B, Laffin LJ, Sarraju A, Nissen SE. Obicetrapib-the Rebirth of CETP Inhibitors? Current atherosclerosis reports. 2024 Oct:26(10):603-608. doi: 10.1007/s11883-024-01231-5. Epub 2024 Aug 16 [PubMed PMID: 39150671]
Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, McGuire DK, Mason D, Tercek G, Nicholls SJ, Kling D, Neild AL, Kastelein J, Davidson M, Ditmarsch M, Nissen SE. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2025 May 17:405(10491):1757-1768. doi: 10.1016/S0140-6736(25)00721-4. Epub 2025 May 7 [PubMed PMID: 40347969]
Level 1 (high-level) evidenceHuang JXF, Yousaf A, Moon J, Ahmed R, Uppal K, Pemminati S. Recent Advances in the Management of Dyslipidemia: A Systematic Review. Cureus. 2025 Mar:17(3):e81034. doi: 10.7759/cureus.81034. Epub 2025 Mar 23 [PubMed PMID: 40264627]
Level 1 (high-level) evidenceGu J, Gupta RN, Cheng HK, Xu Y, Raal FJ. Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary. European journal of preventive cardiology. 2024 Nov 11:31(15):1833-1849. doi: 10.1093/eurjpc/zwae144. Epub [PubMed PMID: 38640433]
Level 1 (high-level) evidenceHafiane A, Ronca A, Incerti M, Rossi A, Manfredini M, Favari E. Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia. European journal of medical research. 2025 Apr 11:30(1):266. doi: 10.1186/s40001-025-02439-0. Epub 2025 Apr 11 [PubMed PMID: 40211340]
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D, ELIPSE HoFH Investigators. Evinacumab for Homozygous Familial Hypercholesterolemia. The New England journal of medicine. 2020 Aug 20:383(8):711-720. doi: 10.1056/NEJMoa2004215. Epub [PubMed PMID: 32813947]
Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, Stefanutti C, Stroes E, Wiegman A, Turner T, Ali S, Banerjee P, Drewery T, McGinniss J, Waldron A, George RT, Zhao XQ, Pordy R, Zhao J, Bruckert E, Raal FJ. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. European heart journal. 2024 Jul 12:45(27):2422-2434. doi: 10.1093/eurheartj/ehae325. Epub [PubMed PMID: 38856678]
Iannuzzo G, Calcaterra I, Gentile M, Stanzione C, De Ruberto F, Di Taranto MD, Fortunato G, Di Minno M. Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study. Advances in therapy. 2025 May:42(5):2465-2479. doi: 10.1007/s12325-025-03160-4. Epub 2025 Apr 2 [PubMed PMID: 40169529]
Level 3 (low-level) evidenceSayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. European heart journal. 2024 Apr 1:45(13):1173-1176. doi: 10.1093/eurheartj/ehad889. Epub [PubMed PMID: 38252107]
Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, Ladden-Stirling AB, Miller M, Orringer CE, Stone NJ. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2021 Aug 31:78(9):960-993. doi: 10.1016/j.jacc.2021.06.011. Epub 2021 Jul 28 [PubMed PMID: 34332805]
Level 3 (low-level) evidenceStroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL, Tsimikas S, Balance Investigators. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. The New England journal of medicine. 2024 May 16:390(19):1781-1792. doi: 10.1056/NEJMoa2400201. Epub 2024 Apr 7 [PubMed PMID: 38587247]
Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano RP, Sabatine MS, Bridge–TIMI 73a Investigators. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. The New England journal of medicine. 2024 May 16:390(19):1770-1780. doi: 10.1056/NEJMoa2402309. Epub 2024 Apr 7 [PubMed PMID: 38587249]
de Moura de Souza M, Mendes BX, Defante MLR, de Athayde de Hollanda Morais BA, Martins OC, Prizão VM, Romaniello G. Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials. Metabolism: clinical and experimental. 2025 Jun:167():156187. doi: 10.1016/j.metabol.2025.156187. Epub 2025 Mar 10 [PubMed PMID: 40074058]
Level 1 (high-level) evidenceYeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, Tsimikas S. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology. 2022 Mar 22:79(11):1035-1046. doi: 10.1016/j.jacc.2021.12.032. Epub [PubMed PMID: 35300814]
Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. Annual review of pharmacology and toxicology. 2024 Jan 23:64():135-157. doi: 10.1146/annurev-pharmtox-031023-100609. Epub 2023 Jul 28 [PubMed PMID: 37506332]
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science (New York, N.Y.). 2001 May 11:292(5519):1160-4 [PubMed PMID: 11349148]
Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Archives of biochemistry and biophysics. 1996 Jan 15:325(2):242-8 [PubMed PMID: 8561503]
Level 3 (low-level) evidenceConde K, Vergara-Jimenez M, Krause BR, Newton RS, Fernandez ML. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. Journal of lipid research. 1996 Nov:37(11):2372-82 [PubMed PMID: 8978489]
Level 3 (low-level) evidenceLarsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. The Medical clinics of North America. 1994 Jan:78(1):225-45 [PubMed PMID: 8283933]
Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993 Apr:87(4 Suppl):III45-53 [PubMed PMID: 8462180]
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). The American journal of cardiology. 2003 Jul 15:92(2):152-60 [PubMed PMID: 12860216]
Level 1 (high-level) evidenceBakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996 Jan 10:275(2):128-33 [PubMed PMID: 8531308]
Level 1 (high-level) evidenceAltmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (New York, N.Y.). 2004 Feb 20:303(5661):1201-4 [PubMed PMID: 14976318]
Level 3 (low-level) evidenceTemel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. The Journal of clinical investigation. 2007 Jul:117(7):1968-78 [PubMed PMID: 17571164]
Level 3 (low-level) evidenceShepherd J, Packard CJ, Morgan HG, Third JL, Stewart JM, Lawrie TD. The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis. 1979 Aug:33(4):433-44 [PubMed PMID: 228682]
Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Archives of internal medicine. 1999 Sep 13:159(16):1893-900 [PubMed PMID: 10493319]
Level 1 (high-level) evidenceMullard A. Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nature reviews. Drug discovery. 2012 Nov:11(11):817-9. doi: 10.1038/nrd3879. Epub [PubMed PMID: 23123928]
Masana L, Zambon A, Schmitt CP, Taylan C, Driemeyer J, Cohen H, Buonuomo PS, Alashwal A, Al-Dubayee M, Kholaif N, Diaz-Diaz JL, Maatouk F, Martinez-Hervas S, Mangal B, Löwe S, Cunningham T. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study. The lancet. Diabetes & endocrinology. 2024 Dec:12(12):880-889. doi: 10.1016/S2213-8587(24)00233-X. Epub 2024 Oct 16 [PubMed PMID: 39426393]
Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. Journal of clinical medicine. 2022 Dec 25:12(1):. doi: 10.3390/jcm12010168. Epub 2022 Dec 25 [PubMed PMID: 36614969]
Arora S, Banerjee S, George A, Bala A, Thingnam SKS, Rohit MK, Dayal D. Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia. Journal of pediatric endocrinology & metabolism : JPEM. 2025 Mar 26:38(3):305-309. doi: 10.1515/jpem-2024-0506. Epub 2025 Jan 1 [PubMed PMID: 40022592]
Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. Journal of lipid research. 1982 Mar:23(3):466-73 [PubMed PMID: 7200504]
Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, Moriarty PM. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. The Annals of pharmacotherapy. 2008 Mar:42(3):341-6. doi: 10.1345/aph.1K604. Epub 2008 Feb 19 [PubMed PMID: 18285559]
Level 2 (mid-level) evidenceKayikçioÄŸlu M, Ozerkan F, Soydan I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. The American journal of cardiology. 1999 Apr 1:83(7):1135-7, A9 [PubMed PMID: 10190536]
Level 1 (high-level) evidenceRuisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. The American journal of cardiology. 2009 Feb 1:103(3):393-4. doi: 10.1016/j.amjcard.2008.09.095. Epub 2008 Nov 19 [PubMed PMID: 19166695]
Afzal MA, Khalid N, Abdullah M, Haiy AU, Hassan MA, Sana H, Elkattawy S, Malik AA, Michael P, Vasudev R, Shamoon F. The Latest Evidence on Bempedoic Acid: Meta-Analysis of Safety and Efficacy in High Cardiovascular Risk Patients With Hypercholesterolemia(⋆). Journal of community hospital internal medicine perspectives. 2024:14(2):12-22. doi: 10.55729/2000-9666.1305. Epub 2024 Mar 4 [PubMed PMID: 38966502]
Level 1 (high-level) evidenceChang JC, Chen YJ, Chen IC, Lin WS, Chen YM, Lin CH. Perinatal Outcomes After Statin Exposure During Pregnancy. JAMA network open. 2021 Dec 1:4(12):e2141321. doi: 10.1001/jamanetworkopen.2021.41321. Epub 2021 Dec 1 [PubMed PMID: 34967881]
Lewek J, Bielecka-DÄ…browa A, Toth PP, Banach M. Dyslipidaemia management in pregnant patients: a 2024 update. European heart journal open. 2024 May:4(3):oeae032. doi: 10.1093/ehjopen/oeae032. Epub 2024 Apr 26 [PubMed PMID: 38784103]
. Atorvastatin. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000420]
. Rosuvastatin. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000421]
. Colestipol. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000452]
. Cholestyramine. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000453]
Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, Srinivasan S, Baker-Smith C, Baum S, Brothers JA, Hartz J, Moriarty PM, Mendell J, Bihorel S, Banerjee P, George RT, Hirshberg B, Pordy R. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2024 Jan 30:149(5):343-353. doi: 10.1161/CIRCULATIONAHA.123.065529. Epub 2023 Oct 20 [PubMed PMID: 37860863]
D'Erasmo L, Steward K, Cefalù AB, Di Costanzo A, Boersma E, Bini S, Arca M, van Lennep JR, Italian and European Working Group on Lomitapide in HoFH. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. European journal of preventive cardiology. 2022 May 5:29(5):832-841. doi: 10.1093/eurjpc/zwab229. Epub [PubMed PMID: 34971394]
Level 2 (mid-level) evidenceRosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of clinical lipidology. 2014 May-Jun:8(3 Suppl):S58-71. doi: 10.1016/j.jacl.2014.03.004. Epub [PubMed PMID: 24793443]
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, TokgözoÄŸlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN, European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European heart journal. 2015 May 1:36(17):1012-22. doi: 10.1093/eurheartj/ehv043. Epub 2015 Feb 18 [PubMed PMID: 25694464]
Level 3 (low-level) evidenceRosenson RS. Current overview of statin-induced myopathy. The American journal of medicine. 2004 Mar 15:116(6):408-16 [PubMed PMID: 15006590]
Level 3 (low-level) evidenceZhou Z, Albarqouni L, Breslin M, Curtis AJ, Nelson M. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ open. 2017 Sep 27:7(9):e017587. doi: 10.1136/bmjopen-2017-017587. Epub 2017 Sep 27 [PubMed PMID: 28963307]
Level 1 (high-level) evidenceGanga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. American heart journal. 2014 Jul:168(1):6-15. doi: 10.1016/j.ahj.2014.03.019. Epub 2014 Apr 12 [PubMed PMID: 24952854]
Level 1 (high-level) evidenceJoy TR, Hegele RA. Narrative review: statin-related myopathy. Annals of internal medicine. 2009 Jun 16:150(12):858-68 [PubMed PMID: 19528564]
Level 3 (low-level) evidenceParker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1:127(1):96-103. doi: 10.1161/CIRCULATIONAHA.112.136101. Epub 2012 Nov 26 [PubMed PMID: 23183941]
Level 1 (high-level) evidenceTobert JA. Efficacy and long-term adverse effect pattern of lovastatin. The American journal of cardiology. 1988 Nov 11:62(15):28J-34J [PubMed PMID: 3055921]
Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyörälä K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Archives of internal medicine. 1996 Oct 14:156(18):2085-92 [PubMed PMID: 8862101]
Level 1 (high-level) evidenceGadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. Journal of molecular and cellular cardiology. 1995 Oct:27(10):2397-402 [PubMed PMID: 8576954]
Level 3 (low-level) evidenceZinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2008 Aug:9(4):223-8. doi: 10.1080/17482960802031092. Epub [PubMed PMID: 18608105]
Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD, Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Annals of internal medicine. 2002 Oct 1:137(7):581-5 [PubMed PMID: 12353945]
Level 3 (low-level) evidenceSmith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Archives of internal medicine. 2003 Mar 24:163(6):688-92 [PubMed PMID: 12639201]
Level 2 (mid-level) evidenceWeismantel D, Danis P. Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? The Journal of family practice. 2001 Nov:50(11):927-8 [PubMed PMID: 11711005]
Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Archives of internal medicine. 2003 Mar 24:163(6):657-9 [PubMed PMID: 12639194]
Level 2 (mid-level) evidenceRosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, Taylor B, Khan I, Manvelian G, White M, Jacobson TA. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovascular drugs and therapy. 2017 Apr:31(2):179-186. doi: 10.1007/s10557-017-6723-4. Epub [PubMed PMID: 28421332]
Level 1 (high-level) evidenceBanach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Lip GY, Dragan S, Mikhailidis DP, Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic proceedings. 2015 Jan:90(1):24-34. doi: 10.1016/j.mayocp.2014.08.021. Epub 2014 Nov 14 [PubMed PMID: 25440725]
Level 1 (high-level) evidenceIllingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Archives of internal medicine. 1994 Jul 25:154(14):1586-95 [PubMed PMID: 8031206]
Level 1 (high-level) evidenceGrundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Archives of internal medicine. 2002 Jul 22:162(14):1568-76 [PubMed PMID: 12123399]
Level 1 (high-level) evidencePasternak RC, Kolman BS. Unstable myocardial ischemia after the initiation of niacin therapy. The American journal of cardiology. 1991 Apr 15:67(9):904-6 [PubMed PMID: 2011995]
Level 3 (low-level) evidenceGarg R, Malinow M, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels. American heart journal. 1999 Dec:138(6 Pt 1):1082-7 [PubMed PMID: 10577438]
Level 1 (high-level) evidenceRobinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England journal of medicine. 2015 Apr 16:372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15 [PubMed PMID: 25773378]
Level 1 (high-level) evidenceSabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England journal of medicine. 2015 Apr 16:372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15 [PubMed PMID: 25773607]
Level 1 (high-level) evidenceZhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, Xie J, Kang LN, Xu B. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC medicine. 2015 Jun 23:13():123. doi: 10.1186/s12916-015-0358-8. Epub 2015 Jun 23 [PubMed PMID: 26099511]
Level 1 (high-level) evidenceBanach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, Paneni F, Parini P, Pirro M, Reiner Ž, Vrablik M, Escobar C. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Progress in cardiovascular diseases. 2023 Jul-Aug:79():2-11. doi: 10.1016/j.pcad.2023.03.001. Epub 2023 Mar 7 [PubMed PMID: 36889490]
Gao Y, Zhang B, Yang J. Evinacumab for the treatment of homozygous familial hypercholesterolemia. Expert review of clinical pharmacology. 2022 Feb:15(2):139-145. doi: 10.1080/17512433.2022.2047934. Epub 2022 Mar 2 [PubMed PMID: 35220876]
Syed YY. Olezarsen: First Approval. Drugs. 2025 Apr:85(4):571-576. doi: 10.1007/s40265-025-02166-0. Epub 2025 Mar 13 [PubMed PMID: 40074987]
Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core evidence. 2019:14():19-30. doi: 10.2147/CE.S174169. Epub 2019 Jul 1 [PubMed PMID: 31308834]
Dixon DL, Buckley LF, Trankle CR, Kadariya D, Abbate A. Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug design, development and therapy. 2017:11():2121-2129. doi: 10.2147/DDDT.S114091. Epub 2017 Jul 11 [PubMed PMID: 28744103]
Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Feingold KR. Triglyceride Lowering Drugs. Endotext. 2000:(): [PubMed PMID: 28402615]
Vahedian-Azimi A, Makvandi S, Banach M, Reiner Ž, Sahebkar A. Fetal toxicity associated with statins: A systematic review and meta-analysis. Atherosclerosis. 2021 Jun:327():59-67. doi: 10.1016/j.atherosclerosis.2021.05.006. Epub 2021 May 16 [PubMed PMID: 34044205]
Level 1 (high-level) evidenceLees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. The New England journal of medicine. 1995 Sep 7:333(10):664-5 [PubMed PMID: 7637734]
Level 3 (low-level) evidenceFichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F, NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (London, England). 2002 Mar 8:16(4):569-77 [PubMed PMID: 11873000]
Level 1 (high-level) evidence. Lomitapide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643777]
. Evinacumab. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 34292698]
McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. The American journal of cardiology. 2006 Apr 17:97(8A):89C-94C [PubMed PMID: 16581336]
Jacobson TA. NLA Task Force on Statin Safety--2014 update. Journal of clinical lipidology. 2014 May-Jun:8(3 Suppl):S1-4. doi: 10.1016/j.jacl.2014.03.003. Epub [PubMed PMID: 24793438]
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24:129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12 [PubMed PMID: 24222016]
Level 1 (high-level) evidenceCanfora I, Pierno S. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives. International journal of molecular sciences. 2024 Sep 8:25(17):. doi: 10.3390/ijms25179727. Epub 2024 Sep 8 [PubMed PMID: 39273674]
Level 3 (low-level) evidenceMarcus MD, Link MS. Omega-3 Fatty Acids and Arrhythmias. Circulation. 2024 Aug 6:150(6):488-503. doi: 10.1161/CIRCULATIONAHA.123.065769. Epub 2024 Aug 5 [PubMed PMID: 39102482]
Patel J, Sheehan V, Gurk-Turner C. Ezetimibe (Zetia): a new type of lipid-lowering agent. Proceedings (Baylor University. Medical Center). 2003 Jul:16(3):354-8 [PubMed PMID: 16278712]
Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. The American journal of cardiology. 2005 Jan 1:95(1):120-2 [PubMed PMID: 15619408]
Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. The American journal of cardiology. 2007 Mar 19:99(6A):47C-55C [PubMed PMID: 17368279]
Sanyal S, Kuvin JT, Karas RH. Niacin and laropiprant. Drugs of today (Barcelona, Spain : 1998). 2010 Jun:46(6):371-8. doi: 10.1358/dot.2010.46.6.1464844. Epub [PubMed PMID: 20571606]
Bays HE, Bloedon LT, Lin G, Powell HA, Louie MJ, Nicholls SJ, Lincoff AM, Nissen SE. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance. Journal of clinical lipidology. 2024 Jan-Feb:18(1):e59-e69. doi: 10.1016/j.jacl.2023.10.011. Epub 2023 Oct 31 [PubMed PMID: 37951797]
Jialal I, Amess W, Kaur M. Management of hypertriglyceridemia in the diabetic patient. Current diabetes reports. 2010 Aug:10(4):316-20. doi: 10.1007/s11892-010-0124-4. Epub [PubMed PMID: 20532703]
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England journal of medicine. 2017 May 4:376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17 [PubMed PMID: 28304224]
Level 2 (mid-level) evidenceBallantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20:107(19):2409-15 [PubMed PMID: 12719279]
Level 1 (high-level) evidenceBhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England journal of medicine. 2019 Jan 3:380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10 [PubMed PMID: 30415628]
Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, REDUCE-IT Investigators. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Circulation. 2020 Feb 4:141(5):367-375. doi: 10.1161/CIRCULATIONAHA.119.044440. Epub 2019 Nov 11 [PubMed PMID: 31707829]
Level 1 (high-level) evidence